- Previous Close
16.59 - Open
17.16 - Bid 17.56 x 100
- Ask 18.74 x 100
- Day's Range
16.00 - 17.20 - 52 Week Range
13.27 - 18.50 - Volume
20,658 - Avg. Volume
93,348 - Market Cap (intraday)
430.866M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
28.00
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
www.contineum-tx.comRecent News: CTNM
Performance Overview: CTNM
Trailing total returns as of 6/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CTNM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CTNM
Valuation Measures
Market Cap
411.57M
Enterprise Value
294.25M
Trailing P/E
22.63
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.66
Price/Book (mrq)
--
Enterprise Value/Revenue
5.88
Enterprise Value/EBITDA
14.80
Financial Highlights
Profitability and Income Statement
Profit Margin
38.25%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
50M
Net Income Avi to Common (ttm)
-447k
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
117.91M
Total Debt/Equity (mrq)
0.50%
Levered Free Cash Flow (ttm)
--